HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Master Thesis

Dépistage du risque de perte d’autonomie chez les patients de plus de 75 ans et de plus de 65 ans avec une ALD : étude de faisabilité de l’outil ICOPE en officine

Abstract : Age-related functional decline and frailty in ageing can be detected using the ICOPE tool proposed and validated by the World Health Organization (WHO) in its program on "healthy ageing". Screening for the risk of loss of autonomy then allows the implementation of targeted preventive actions. Through their presence throughout the country, community pharmacies represent potential key players for implementing programs of prevention in primary care. However, to date, the feasibility and acceptability of the use of this ICOPE tool is not clearly documented, feedback has been recorded on the use of ICOPE in pharmacies, but few are evaluated. The objective of this work is to test the feasibility of using the ICOPE tool in community pharmacies for patients over 75 years or over 65 years with a long duration disease. It aims also at determining the prevalence of functional decline among aged patients attending primary care pharmacies. Over a period of 3 months, the ADL scale as well as the ICOPE tool were offered over the counter to the entire target population. After obtaining consent, assessments via the ADL scale and step 1 of ICOPE were carried out, recorded and analyzed. The primary endpoints were the test’s acceptance rate, and the average duration of the screening. The secondary endpoint was the prevalence of functional decline as assessed by the score on the ADL and ICOPE scale. The results shown : an acceptance rate of the ICOPE test of 88% (95 agreements including 6 lost to follow-up, out of 108 patients invited to participate), an average screening time of 6 minutes and 16 seconds. 96.6 % of the screened patients shown at least one impaired intrinsic function, and therefore an ICOPE considered to be abnormal. The function most often impaired was the vision in 73 % of patients, cognition is the second most impaired function (70.8 %). Mobility is impaired in 10.1 % of patients with a successful timed chair lift test for 80 patients. Screening for the decline in intrinsic capacities via the use of step 1 of ICOPE by the community pharmacist seems very easily achievable, due to its ease of implementation and its short duration of screening. The involvement of the community pharmacist seems essential for the deployment of ICOPE throughout the general population (awareness, follow-up every 4 to 6 months, information). The results also show the high prevalence of functional decline of the community-dwelling aged population, with 96.6 % of patients having an abnormal ICOPE.
Document type :
Master Thesis
Complete list of metadata

Contributor : Jean-Hugues Morneau Connect in order to contact the contributor
Submitted on : Friday, July 23, 2021 - 11:11:40 AM
Last modification on : Sunday, July 25, 2021 - 3:26:00 AM
Long-term archiving on: : Sunday, October 24, 2021 - 6:21:57 PM


  • HAL Id : dumas-03297154, version 1


Mathilde Camus-Gabriel. Dépistage du risque de perte d’autonomie chez les patients de plus de 75 ans et de plus de 65 ans avec une ALD : étude de faisabilité de l’outil ICOPE en officine. Sciences pharmaceutiques. 2021. ⟨dumas-03297154⟩



Record views


Files downloads